Cancer Research Technology
Log in Register
Menu

Anti-N6-methyladenosine (m6A), Recombinant [17-3-4-1]

Info

Catalogue Number 153275
Applications IP DB
Antigen/Gene or Protein Targets N6-methyladenosine-5'-mono-phosphate
Reactivity Human, Mouse and Saccharomyces cerevisiae
Relevance Recombinant monoclonal antibody which binds to m6A modification found in RNA and allows for analysis of methylated transcriptomes. This can be used to investigate how m6A modifications regulates gene expression.

Background and Research Application
N6-Methyladenosine (m6A) is an abundant modification found in mRNA, tRNA, snRNA, as well as long non-coding RNA, in all species. RNA adenosine methylation is catalysed by a multicomponent complex composed of METTL3/MT-A70, METTL14, and WTAP in mammals. METTL3 & METTL14 are responsible for the methyltransferase activity of the complex, and WTAP mediates substrate recruitment.
The m6A antibody was created to identify m6A containing messages within RNA and helped identify the transcripts of three key, early regulators of meiosis, IME1, IME2 and IME4 itself as being methylated in RNA transcripts. This is a recombinant version of the anti-N6-methyladenosine monoclonal antibody. Anti-m6A. helped narrow down the position of m6A in IME2 as towards the 3’ end.
Anti-N6-methyladenosine will allow for analysis of methylated transcriptomes, and could aid understanding in how the m6A base modification regulates gene expression.
Host Mouse
Immunogen Hapten N6-methyladenosine-5'-mono-phosphate conjugated to BSA of all N6-methyladenosine
Subclass IgG1 kappa
Formulation PBS
Concentration 1mgml-1
Research Area Epigenetics & Nuclear Signalling
Immunogen UniProt ID Q8BGW1
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
It was shown that mutations in the m6A demethylase gene FTO, which cause a decrease of m6A levels, are associated with an increased risk for obesity and type 2 diabetes.

This antibody recognises N6-methyladenosine in both modified RNA AND DNA (see associated data).
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
Application Note: For immunoprecipitation the best results are obtained by pre-binding the antibody to the beads before washing off unbound immunoglobulin. It is recommended to start with an excess of antibody in order to ensure the Protein G beads are saturated.

IP protocol was derived from Dominissini et al., 2013 Nat Protoc. 8(1):176-89.

Concentration
1mg/ml as standard

Related
Six products based on this clone:
- Anti-N6-methyladenosine [17-3-4-1], Mouse IgG1, Lambda
- Anti-N6-methyladenosine [17-3-4-1], Rabbit IgG, Lambda
- Anti-N6-methyladenosine [17-3-4-1], Human IgG4-S228P, Lambda
- Anti-N6-methyladenosine [17-3-4-1], Human IgG1, Lambda
- Anti-N6-methyladenosine [17-3-4-1], Human IgG1, Lambda, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-N6-methyladenosine [17-3-4-1], Mouse IgG2a, Lambda

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Bodi et al. 2010. Nucleic Acids Res. 38(16):5327-35. PMID: 20421205.


Add a reference

References: 1 entry

Original hybridoma first published in: Bodi et al. 2010. Nucleic Acids Res. 38(16):5327-35. PMID: 20421205.


Add a reference

Inventor Information